Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs

Arthritis and Rheumatism

Volumn 46, Issue 8, 2002, Pages 2195-2200

  Smalley, Walter ^a,b   Stein, C Michael ^a   Arbogast, Patrick G ^a   Eisen, Glenn ^a   Ray, Wayne A ^a   Griffin, Marie ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b C 2104 MCN ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; BROMFENAC; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN CALCIUM; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC TROMETAMOL; MECLOFENAMATE SODIUM; MEFENAMIC ACID; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SULINDAC; TOLMETIN; UNINDEXED DRUG;

ADULT; AGE; AGED; ANALGESIA; ARTICLE; DOSE RESPONSE; DRUG SELECTIVITY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PAIN; PEPTIC ULCER; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; STOMACH PROTECTION; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PEPTIC ULCER; RISK FACTORS; TENNESSEE;

EID: 0036673865     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10425     Document Type: Article

References (26)

1. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
3. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
4. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
5. Risks and costs of upper gastrointestinal disease attributable to NSAIDs
6. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
7. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: A meta-analysis
8. A guideline for the treatment and prevention of NSAID-induced ulcers
9. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
10. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
11. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
12. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: Ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group
13. Use of Medicaid data for pharmacoepidemiology
14. Nonsteroidal anti-inflammatory drug-associated gastrointestinal complications: Guidelines for prevention and treatment
15. Prevention of NSAID-induced gastroduodenal ulcers
16. Osteoarthritis management: The role of cyclooxygenase-2-selective inhibitors
17. The economic implications of cyclooxygenase-2-specific inhibitors
18. The Swedish ACCES model: Predicting the health economic impact of celecoxib in Rheumatology
19. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis
20. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective
21. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland
22. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
23. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
24. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia
25. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes